Algeria Croatia EgyptFranceGreece ItalyJordanLebanonLybiaMorocco PortugalSyriaSloveniaSpainTunisiaTurkeyPalestine Albania Cyprus MacedoniaMalta Mediterranean.

Slides:



Advertisements
Similar presentations
Dr Andrea Micheli Descriptive Epidemiology and Health Planning Unit Istituto Nazionale Tumori Milan WP-10 - CANCER EXCHANGE OF INFORMATION ON THE PROJECT.
Advertisements

The importance of cancer data & registries to understand the cancer burden (EUROCHIP) ECPC Cancer Summit 2010, October 2010 Dr. Andrea Micheli Director.
FROM EUROCHIP-1 TO EUROCHIP-2 EUROCHIP-2 - The action Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL.
HEALING THE CRISIS The urgent need to improve public health in SEE Ana Stavljenic-Rukavina Zagreb University School of Medicine and OSI NY:Sub-board for.
EUROCHIP-2 the action Health Indicators for Monitoring Cancer in Europe Public Health Program EUROPEAN.
Lung Cancer. Lung Cancer Incidence 1950s Male/Female ratio 6:1, this is now 7:5. (decreasing male smoking rates, increasing female smoking rates). Approximately.
April 6, o What is cancer? o Cancer statistics o Cancer prevention and early detection o Cancer disparities o Cancer survivorship o Cancer research.
Introduction to Epidemiology Manish Chaudhary. Basic Concept in Epidemiology Epidemiology is the study of the occurrence, distribution and determinants.
Cancer inequalities in Europe UKACR & NCIN Conference, 17/18 June 2010 Dr. Andrea Micheli Director Descriptive Study and Health Planning Unit Fondazione.
Global Cancer Epidemic: Impact, Challenges and Future Trends
Ora Paltiel, MD, MSc Braun School of Public Health & Community Medicine Hebrew University of Jerusalem Hadassah Medical Organization Israel.
© Cancer Research UK 2007 Registered charity number Lung cancer and smoking – UK November 2009 The statistics in this presentation are based on.
Cancer inequalities in Europe Kielce, Polish conference on cancer, 13/15 June 2011 Dr. Andrea Micheli Director Descriptive Study and Health Planning Unit.
EUROCHIP - EUROpean Cancer Health Indicators Project A project supported by the European Commission Andrea Micheli 1, Paolo Baili 1, Carmen Martinez 2,
© Cancer Research UK 2011 Registered charity in England and Wales ( ) and Scotland (SC041666) Breast Cancer - UK December 2011 For more information.
World Burden of Cancer Epi 242 Cancer Epidemiology Binh Goldstein, Ph.D. October 7, 2009.
How do cancer rates in your area compare to those in other areas?
Status of cancer in Europe Now ESMO, 9-10 October 2010 Dr. Andrea Micheli Director Descriptive Studies and Health Planning Unit Fondazione IRCCS “Istituto.
Biology in Focus, HSC Course Glenda Childrawi, Margaret Robson and Stephanie Hollis A Search For Better Health Topic 11: Epidemiology.
Introduction to Epidemiology
Program Planning Program Planning. It is a document which defines a health problem or a group of problems in one field, describes the goals set up to.
Recent advances in the management of colorectal cancer Vilnius, May 6-7 Epidemiology of colorectal cancer: what we can learn from Lithuania Juozas Kurtinaitis.
Disparities in Cancer September 22, Introduction Despite notable advances in cancer prevention, screening, and treatment, a disproportionate number.
Dr Jesme Baird The Roy Castle Lung Cancer Foundation, UK and ECPC.
STRENGTHENING CENTER FOR PREVENTION IN PRIMARY HEALTH CARE CENTER “ZEMUN” Dr Olivera M. ĆIRKOVIĆ Dr Olivera M. ĆIRKOVIĆ Prof. dr Milica Prostran Dr Mladen.
NOT ALL PAST SUCCESSES IN CANCER RESEARCH HAVE BEEN FOLLOWED BY ACTIONS EUROCHIP-2 THE ACTION Project & news EUROCHIP-2 THE ACTION Project & news Public.
Health Consultation: Evaluation of Cancer Incidence in Census Tracts of Attleboro and Norton, Massachusetts: Suzanne K. Condon Associate Commissioner.
EUROCHIP-2 ACTIVITY ON CERVICAL CANCER SCREENING BULGARIA.
BC Jung A Brief Introduction to Epidemiology - IX (Epidemiologic Research Designs: Case-Control Studies) Betty C. Jung, RN, MPH, CHES.
ANALYTICAL STUDIES Prospective Studies COHORT Prepared by: Dr. Sahar Sabbour Community Medicine Department.
Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,
Moving Cancer Research from the Lab to the Population: The Final Step in Translational Research Presented by: Thomas C. Tucker, PhD, MPH Associate Director.
EUROCHIP-2 EUROCHIP-2 - The Action Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL.
 Subhendu De, Wonsuk Yoo Institute of Public and Preventative Health (IPPH), Georgia Regents University On Summer Public Health Scholars Program (SPHSP)
European Union against cancer The EUROCHIP project 1st International Cancer Control Congress Vancouver, October 2005 Public Health Program EUROPEAN.
© Cancer Research UK 2006 Registered charity number The statistics in this presentation are based on the Bowel CancerStats report published in.
Associated Web sites CustomizableMaps The Atlas On-Line.
13 site specific articles 13 site specific articles Adult patients (age 15+) Adult patients (age 15+) Survival by subsite, tumour morphology, stage Survival.
Tools to Access the Latest Cancer Statistics Paul Miller Washington Reporting Fellowships program presentation April 15, 2013.
© Cancer Research UK 2011 Registered charity in England and Wales ( ) and Scotland (SC041666) Colorectal Cancer - UK December 2011 For more information.
Dr Heather O Dickinson Department of Child Health University of Newcastle
Incorporating Multiple Evidence Sources for the Assessment of Breast Cancer Policies and Practices J. Jackson-Thompson, Gentry White, Missouri Cancer Registry,
Diversity and the Burden of Cancer David C. Momrow, M.P.H. Senior Vice President of Cancer Control American Cancer Society – Eastern Division January 21,
EUROCHIP-Italia in EUROCHIP-2 Health Indicators for Monitoring Cancer in Europe Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION.
Research and Methodology
The Inflammatory Breast Cancer Cancer Registry Paul H. Levine, M.D. Paul H. Levine, M.D. The George Washington University School of Public Health and Health.
Epidemiology 242: Cancer Epidemiology Zuo-Feng Zhang, MD, PhD Fall Quarter, 2009.
HEALTH A state of complete physical, mental and social well being and not merely the absence of disease or infirmity and ability to lead a socially and.
Stomach – UK July 2007.
Peterson-Kaiser Health System Tracker What are recent trends in cancer spending and outcomes?
National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.
Cancer inequalities in Europe UKACR & NCIN Conference, 17/18 June 2010 Dr. Andrea Micheli Director Descriptive Study and Health Planning Unit Fondazione.
South West Public Health Observatory The work of the South West Public Health Observatory on End of Life care SEPHIG January 2011 Andy Pring.
The Cancer Registry of Norway Jan F Nygård Head of the IT-department.
Cancer in Ontario: Overview A Statistical Report.
Where can I find data on cancer? Victoria H Coupland London Knowledge and Intelligence Team 20 February 2014.
By: Dr Khalid El Tohami INTRODUCTION TO PUBLIC HEALTH AND EPIDEMIOLOGY (1)
© 2010 Jones and Bartlett Publishers, LLC. Chapter 5 Descriptive Epidemiology According to Person, Place, and Time.
A Search For Better Health Topic 11: Epidemiology
Italy - Evidence package
Non-Communicable Diseases Risk Factors Survey in Georgia
Global Cancer Agenda Julie Gralow, M.D University of Washington
Bronx Community Health Dashboard: Other Cancers Last Updated: 01/09/2018 See last slide for more information about this project.
Review – First Exam Chapters 1 through 5
Non-Hodgkin Lymphoma (C82-C86): 2014
Review in slides Republic of Korea
Assessment of Breast and Colorectal Cancer Surgery in Manitoba
Trends in cancer Incidence in the Republic of Mauritius,
Siwei Zhang Rongshou Zheng
Cancer prevention policy in the EU:
Presentation transcript:

Algeria Croatia EgyptFranceGreece ItalyJordanLebanonLybiaMorocco PortugalSyriaSloveniaSpainTunisiaTurkeyPalestine Albania Cyprus MacedoniaMalta Mediterranean Task Force for Cancer Control (MTCC) AIMS: To unify efforts to eliminate suffering and reduce mortality of cancer through decreasing incidence of adv. disease

Massimo Crespi, MD on behalf of the MOS Epidemiology Group M Barchana, AS Ibrahim, N Mikhail, S Eser, M Strnad, V Ramazzotti

Introduction Mediterranean coastal populations share a common historical heritage and cultural roots B U T genetic background and lifestyle habits diverged in the centuries, mostly in the last 200 years, as a consequence of industrialization R E S U L T great difference in cancer incidence Mediterranean coastal populations share a common historical heritage and cultural roots B U T genetic background and lifestyle habits diverged in the centuries, mostly in the last 200 years, as a consequence of industrialization R E S U L T great difference in cancer incidence

Cancer – All sites

Aims coastal Perform a comprehensive analysis based on solid (not extrapolated) data for Mediterranean coastal populations and intended as a baseline for future, more analytical studies Data at National levelSelected coastal areas

GLOBOCAN methodology GLOBOCAN methodology Sources of GLOBOCAN data Reports of National and Regional Registries (when available) Relative Frequency data. Data of neighboring countries Mathematical modeling Extrapolation Sources of GLOBOCAN data Reports of National and Regional Registries (when available) Relative Frequency data. Data of neighboring countries Mathematical modeling Extrapolation

MOS methodology The most frequent cancer sites were examined for 20 countries, standardized to ASR world as crude, age specific and age-adjusted (x 100,000y) by the most recently data available ( ) from National/Regional Cancer Registries The cancer sites considered are : All Cancer-sites combined Breast (F)Prostate (M) ColorectalUrinary bladder Non Hodgkin Lymphoma Lung The most frequent cancer sites were examined for 20 countries, standardized to ASR world as crude, age specific and age-adjusted (x 100,000y) by the most recently data available ( ) from National/Regional Cancer Registries The cancer sites considered are : All Cancer-sites combined Breast (F)Prostate (M) ColorectalUrinary bladder Non Hodgkin Lymphoma Lung

Why Incidence ? Cancer Incidence rates are the net effect of internal (genetic) and external (environmental) causal and preventive factors and provide the clearest measure of exposure to the above factors at the population level

What we achieved A description of cancer incidence in populations sharing a common past history but with significant differences arising in the modern context in respect to ethnicity, religion, socio- economic status, level of industrialization and GDP All data are available at

Cancer Incidence Globocan 2002 BREAST 29.0 % 27.1 % Southern Europe Northern Africa

Lung Cancer

Colorectal Cancers

Cancer Incidence Globocan 2002 COLON 4.7% 13.3 % Southern Europe Northern Africa Southern Europe Northern Africa

The ultimate efficiency indicator of preventive diagnostic therapeutic strategies and the frame for evaluation of Health Systems and the frame for evaluation of Health Systems The ultimate efficiency indicator of preventive diagnostic therapeutic strategies and the frame for evaluation of Health Systems and the frame for evaluation of Health Systems Survival of Cancer Patients

EPICENTRO.ISS.IT EUROCARE.IT Eurocare-3 study Annals of Oncology 2003 (Suppl. 5) vol. 14 (Not EU) England Scotland Wales 5y survival of CRC from Cancer Registries

Economics are always a significant determinant of outcomes…

Disks area is proportional to National Health Expenditure ($ PPP) del paese $ PPP: Parity Purchasing Power per capita (US $) - From: OECD 2002 for GIP and NHE; EUROCARE-3 for survival Gross Internal Product (1997) and all cancer 5y-Survival (adj. for age and site) (%) - Males

Total expenditure on health as percentage of GDP (WHO data)

Conclusions In comparison, GLOBOCAN data differs substantially from the ones of MOS, either in over- or under-estimation. The MOS data are on coastal population and based on Cancer Registries data. We propose them as a baseline information to clinicians, researchers and Health authorities for proper actions In comparison, GLOBOCAN data differs substantially from the ones of MOS, either in over- or under-estimation. The MOS data are on coastal population and based on Cancer Registries data. We propose them as a baseline information to clinicians, researchers and Health authorities for proper actions

Final message Eat better Smoke less Decrease infections Decrease pollution Increase Health Budgets !!

Causal factors Preventive factors Which are the priority actions?